MOTS-c is a mitochondrial-encoded peptide; NAD+ is a coenzyme every cell already uses. How they differ in chemistry, human evidence and regulatory status.
By the MOTS-C Peptide editorial team·Last reviewed ·Sources: editorially approved
Short answer
These are different categories of molecule. NAD+ is a coenzyme every cell already makes and uses across hundreds of reactions [PubChem]. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA whose molecular target has not been identified [FDA 2026]. They share a marketing category, not a mechanism.
MOTS-c and NAD+ compared field by field. Each column describes that substance only; the rows are not scores.
MOTS-c
NAD+
Kind of molecule
A peptide, 16 amino acids
A dinucleotide coenzyme
Molecular formula
C₁₀₁H₁₅₂N₂₈O₂₂S₂
C₂₁H₂₇N₇O₁₄P₂
Molecular weight
2174.6 g/mol
663.4 g/mol
Where it comes from
Encoded in mitochondrial DNA (MT-RNR1)
Synthesised by every cell from precursors such as nicotinamide, NR and NMN
Established role
Still being worked out; no identified target
Electron carrier and substrate in hundreds of reactions; the biochemistry is textbook
Usual research question
Does giving this peptide change anything?These are different questions, which is why the two literatures are not comparable.
Does raising declining levels change anything?
Randomised human trials published
None
Yes, of precursors such as NMN and NR
Regulatory position
Not approved; FDA staff recommended against compounding listing in 2026
Precursors sold as dietary supplements in the US; not approved drugs
Prohibited in sport
Yes, at all times (WADA S4)
Not listed
Why the comparison is awkward
NAD+ research asks a restoration question. Levels are reported to fall with age, and the field tests whether raising them with precursors such as nicotinamide riboside or nicotinamide mononucleotide changes anything measurable [Rajman 2018]. The molecule’s role is not in doubt; what is in doubt is whether topping it up helps.
MOTS-c research asks a more basic question. The 2015 discovery work proposed a chain running from folate-cycle inhibition through AICAR accumulation to AMPK activation [Lee et al. 2015], and the field is still establishing whether that is how the peptide acts, in what tissues, and through what target. Asking which is “better” is like asking whether a known vitamin beats a candidate drug.
Does MOTS-c affect NAD+?
Not according to anything in this index. None of the 253 indexed MOTS-c publications reports a measurement of NAD+ levels after MOTS-c, and no study in the corpus tests the two together. Material describing MOTS-c as an “NAD+ booster” is making a claim with no support in the MOTS-c literature.
There is a loose conceptual adjacency, in that both touch cellular energy sensing, and AMPK is responsive to the cell’s energy state. But adjacency in a textbook diagram is not evidence of an interaction, and no indexed study has looked for one.
Regulatory status differs sharply
NAD+ precursors are sold in the United States as dietary supplements, a category that involves no FDA approval for safety or effectiveness but does place them in a lawful consumer market. MOTS-c sits outside that: not approved, not a supplement ingredient, and the subject of a 2026 FDA review in which staff recommended against adding it to the compounding list [FDA 2026]. It is also prohibited in sport at all times [WADA 2026]. See regulatory status.
For what the MOTS-c metabolic research actually shows, see metabolic research; for the closest comparison with real overlapping research behind it, see MOTS-c vs humanin.
Frequently asked questions
What is the difference between MOTS-c and NAD+?
They are not the same kind of thing. NAD+ is a coenzyme that every cell already uses in hundreds of reactions, central to energy metabolism. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA whose function is still being worked out and whose molecular target is unknown.
Is MOTS-c an NAD+ booster?
No study in this index reports that MOTS-c raises NAD+ levels. The two are grouped in marketing as "mitochondrial" or "longevity" products, which is a commercial category rather than a biological one.
Which has more human evidence?
NAD+ precursors have been tested in randomised controlled trials in people, including a trial of nicotinamide mononucleotide in women with prediabetes. No published trial has given MOTS-c to people and reported outcomes.
Can you take them together?
This site does not give usage guidance for either, and no study in this index has combined them. There is no evidence on which to base an answer.
Are NAD+ supplements approved?
NAD+ precursors such as nicotinamide riboside are sold as dietary supplements in the United States, a category that does not involve FDA approval for safety or effectiveness. MOTS-c is not approved and is not a supplement ingredient.
References
Lee C, Zeng J, Drew BG et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. PubMed 25738459 · doi:10.1016/j.cmet.2015.02.009 · Study record[Animal, tier C]
National Center for Biotechnology Information. PubChem Compound CID 146675088: Mots-c. Source[retrieved 2026-11-11]
National Center for Biotechnology Information. PubChem Compound CID 5892: NAD (nadide). Source[retrieved 2026-11-11]
Rajman L, Chwalek K, Sinclair DA, Cell Metab (2018-03-06). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Source[retrieved 2026-11-11]
Yoshino M et al., Science (2021-06-11). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Source[retrieved 2026-11-11]
U.S. Food and Drug Administration (2026-05-11). FDA Briefing Document: MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate). Source[retrieved 2026-11-11]
ClinicalTrials.gov (2026-04-01). MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745). Source[retrieved 2026-11-11]
World Anti-Doping Agency (2026-01-01). The Prohibited List (S4 Hormone and Metabolic Modulators: activators of AMP-activated protein kinase). Source[retrieved 2026-11-11]